Juvenile Dermatomyositis Differential Diagnoses

1. DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol. 2020 Feb. 82 (2):267-81. [QxMD MEDLINE Link].

2. Rider LG, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 1997 Aug. 23(3):619-55. [QxMD MEDLINE Link].

3. Rider LG, Miller FW. Idiopathic inflammatory muscle disease: clinical aspects. Baillieres Best Pract Res Clin Rheumatol. 2000 Mar. 14(1):37-54. [QxMD MEDLINE Link].

4. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975 Feb 13. 292(7):344-7. [QxMD MEDLINE Link].

5. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975 Feb 20. 292(8):403-7. [QxMD MEDLINE Link].

6. Brown VE, Pilkington CA, Feldman BM, Davidson JE,. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford). 2006 Aug. 45(8):990-3. [QxMD MEDLINE Link].

7. Spencer CH, Hanson V, Singsen BH, Bernstein BH, Kornreich HK, King KK. Course of treated juvenile dermatomyositis. J Pediatr. 1984 Sep. 105(3):399-408. [QxMD MEDLINE Link].

8. Constantin T, Ponyi A, Orban I, Molnar K, Derfalvi B, Dicso F. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary--clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity. 2006 May. 39(3):223-32. [QxMD MEDLINE Link].

9. Targoff IN. Myositis specific autoantibodies. Curr Rheumatol Rep. 2006 Jun. 8(3):196-203. [QxMD MEDLINE Link].

10. Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol. 2007 Oct. 157(4):637-44. [QxMD MEDLINE Link].

11. Hiketa T, Matsumoto Y, Ohashi M, Sasaki R. Juvenile dermatomyositis: a statistical study of 114 patients with dermatomyositis. J Dermatol. 1992 Aug. 19(8):470-6. [QxMD MEDLINE Link].

12. Engel AG, Arahata K, Emslie-Smith A. Immune effector mechanisms in inflammatory myopathies. Res Publ Assoc Res Nerv Ment Dis. 1990. 68:141-57. [QxMD MEDLINE Link].

13. Engel AG, Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol. 1986 Jul. 17(7):704-21. [QxMD MEDLINE Link].

14. Crowe WE, Bove KE, Levinson JE, Hilton PK. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum. 1982 Feb. 25(2):126-39. [QxMD MEDLINE Link].

15. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003 Sep 20. 362(9388):971-82. [QxMD MEDLINE Link].

16. Li CK, Varsani H, Holton JL, Gao B, Woo P, Wedderburn LR. MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol. 2004 Mar. 31(3):605-9. [QxMD MEDLINE Link].

17. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology. 2007 Nov 20. 69(21):2008-19. [QxMD MEDLINE Link].

18. Lopez de Padilla CM, Vallejo AN, McNallan KT, Vehe R, Smith SA, Dietz AB. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum. 2007 May. 56(5):1658-68. [QxMD MEDLINE Link].

19. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986 Feb 6. 314(6):329-34. [QxMD MEDLINE Link].

20. Dalakas MC. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am. 2002 Nov. 28(4):779-98, vi. [QxMD MEDLINE Link].

21. Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P. Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol. 2003 Apr. 137(1-2):125-33. [QxMD MEDLINE Link].

22. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature. 2008 Jun 19. 453(7198):1051-7. [QxMD MEDLINE Link].

23. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008 May. 8(5):337-48. [QxMD MEDLINE Link].

24. López De Padilla CM, Vallejo AN, Lacomis D, McNallan K, Reed AM. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum. 2009 Apr. 60(4):1160-72. [QxMD MEDLINE Link].

25. Tezak Z, Hoffman EP, Lutz JL, Fedczyna TO, Stephan D, Bremer EG. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol. 2002 Apr 15. 168(8):4154-63. [QxMD MEDLINE Link]. [Full Text].

26. Nagaraju K, Rider LG, Fan C, Chen YW, Mitsak M, Rawat R, et al. Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis. 2006 Feb 20. 3:2. [QxMD MEDLINE Link]. [Full Text].

27. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005. 23:275-306. [QxMD MEDLINE Link].

28. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005 May. 57(5):664-78. [QxMD MEDLINE Link].

29. McNiff JM, Kaplan DH. Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J Cutan Pathol. 2008 May. 35(5):452-6. [QxMD MEDLINE Link].

30. Niewold TB, Wu SC, Smith M, Morgan GA, Pachman LM. Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics. 2011 May. 127(5):e1239-46. [QxMD MEDLINE Link]. [Full Text].

31. Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995 Aug. 34(8):732-6. [QxMD MEDLINE Link].

32. Pachman LM, Hayford JR, Chung A, Daugherty CA, Pallansch MA, Fink CW. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol. 1998 Jun. 25(6):1198-204. [QxMD MEDLINE Link].

33. Massa M, Costouros N, Mazzoli F, et al. Self Epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum. 2002. 46(11):3015-3025.

34. Christensen ML, Pachman LM, Schneiderman R, Patel DC, Friedman JM. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum. 1986 Nov. 29(11):1365-70. [QxMD MEDLINE Link].

35. Chevrel G, Calvet A, Belin V, Miossec P. Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle. Rheumatology (Oxford). 2000 Sep. 39(9):1037-9. [QxMD MEDLINE Link]. [Full Text].

36. Lewkonia RM, Horne D, Dawood MR. Juvenile dermatomyositis in a child infected with human parvovirus B19. Clin Infect Dis. 1995 Aug. 21(2):430-2. [QxMD MEDLINE Link].

37. Zampieri S, Ghirardello A, Iaccarino L, Briani C, Sarzi-Puttini P, Atzeni F. Polymyositis-dermatomyositis and infections. Autoimmunity. 2006 May. 39(3):191-6. [QxMD MEDLINE Link].

38. Albani, S. Infection and molecular mimicry in autoimmune diseases of childhood. Clin Exp Rheumatol. 1994. 12 (Suppl 10):S35-41.

39. Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007 Jan-Feb. 13(1-2):59-68. [QxMD MEDLINE Link]. [Full Text].

40. Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007 Nov. 56(11):3784-92. [QxMD MEDLINE Link]. [Full Text].

41. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005 May. 57(5):664-78. [QxMD MEDLINE Link].

42. Dourmishev AL, Dourmishev LA. Dermatomyositis and drugs. Adv Exp Med Biol. 1999. 455:187-91. [QxMD MEDLINE Link].

43. Kass E, Straume S, Mellbye OJ, Munthe E, Solheim BG. Dermatomyositis associated with BCG vaccination. Scand J Rheumatol. 1979. 8(3):187-91. [QxMD MEDLINE Link].

44. Adams C, August CS, Maguire H, Sladky JT. Neuromuscular complications of bone marrow transplantation. Pediatr Neurol. 1995 Jan. 12(1):58-61. [QxMD MEDLINE Link].

45. Reed AM, Pachman L, Ober C. Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501. Hum Immunol. 1991 Dec. 32(4):235-40. [QxMD MEDLINE Link].

46. Reed AM, Stirling JD. Association of the HLA-DQA1*0501 allele in multiple racial groups with juvenile dermatomyositis. Hum Immunol. 1995 Nov. 44(3):131-5. [QxMD MEDLINE Link].

47. Mamyrova G, O'Hanlon TP, Monroe JB, Carrick DM, Malley JD, Adams S, et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum. 2006 Dec. 54(12):3979-87. [QxMD MEDLINE Link]. [Full Text].

48. Reed AM, McNallan K, Wettstein P, Vehe R, Ober C. Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis?. J Immunol. 2004 Apr 15. 172(8):5041-6. [QxMD MEDLINE Link]. [Full Text].

49. Reed AM, Picornell YJ, Harwood A, Kredich DW. Chimerism in children with juvenile dermatomyositis. Lancet. 2000 Dec 23-30. 356(9248):2156-7. [QxMD MEDLINE Link].

50. Artlett CM, Ramos R, Jiminez SA, Patterson K, Miller FW, Rider LG. Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. Lancet. 2000 Dec 23-30. 356(9248):2155-6. [QxMD MEDLINE Link].

51. Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum. 2000 Oct. 43(10):2368-77. [QxMD MEDLINE Link].

52. Fedczyna TO, Lutz J, Pachman LM. Expression of TNFalpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele. Clin Immunol. 2001 Aug. 100(2):236-9. [QxMD MEDLINE Link].

53. Rider LG, Artlett CM, Foster CB, Ahmed A, Neeman T, Chanock SJ, et al. Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clin Exp Immunol. 2000 Jul. 121(1):47-52. [QxMD MEDLINE Link]. [Full Text].

54. Kelly JC. Juvenile Dermatomyositis May Be Triggered by UV Exposure. Medscape Medical News. Available at http://www.medscape.com/viewarticle/807438. Accessed: March 19, 2015.

55. Shah M, Targoff IN, Rice MM, Miller FW, Rider LG. Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. Arthritis Rheum. 2013 Jul. 65(7):1934-41. [QxMD MEDLINE Link]. [Full Text].

56. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003 Jun 15. 49(3):300-5. [QxMD MEDLINE Link].

57. Pachman LM, Lipton R, Ramsey-Goldman R, Shamiyeh E, Abbott K, Mendez EP. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum. 2005 Apr 15. 53(2):166-72. [QxMD MEDLINE Link].

58. Bitnum S, Daeschner CW Jr, Travis LB, Dodge WF, Hopps HC. Dermatomyositis. J Pediatrics. 1964. 64:101-31.

59. Huber AM, Feldman BM. Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going?. Curr Rheumatol Rep. 2005/12. 7(6):441-6.

60. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000 Mar. 43(3):541-9. [QxMD MEDLINE Link].

61. Miller LC, Michael F, Kim Y. Childhood dermatomyositis: Clinical course and long-term follow-up. Clin Pediatr. 1987. 26(11):5661-6.

62. Taieb A, Guichard C, Salamon R, Maleville J. Prognosis in juvenile dermatopolymyositis: a cooperative retrospective study of 70 cases. Pediatr Dermatol. 1985 Jul. 2(4):275-81. [QxMD MEDLINE Link].

63. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum. 2004 May. 50(5):1595-603. [QxMD MEDLINE Link].

64. Rider LG. Calcinosis in juvenile dermatomyositis: pathogenesis and current therapies. Pediatric Rheumatology Online Journal. 2003. 1(2):[Full Text].

65. Boulman N, Slobodin G, Rozenbaum M, Rosner I. Calcinosis in rheumatic diseases. Semin Arthritis Rheum. 2005 Jun. 34(6):805-12. [QxMD MEDLINE Link].

66. Hundley JL, Carroll CL, Lang W, Snively B, Yosipovitch G, Feldman SR. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol. 2006 Feb. 54(2):217-20. [QxMD MEDLINE Link].

67. Sallum AM, Pivato FC, Doria-Filho U, et al. Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J). 2008. 84(1):68-74.

68. Sag E, Demir S, Bilginer Y, et al. Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis. Semin Arthritis Rheum. 2021 Feb. 51 (1):95-100. [QxMD MEDLINE Link].

69. Peloro TM, Miller OF 3rd, Hahn TF, Newman ED. Juvenile dermatomyositis: a retrospective review of a 30-year experience. J Am Acad Dermatol. 2001 Jul. 45(1):28-34. [QxMD MEDLINE Link].

70. Braunstein EM, White SJ. Pneumatosis intestinalis in dermatomyositis. Br J Radiol. 1980 Oct. 53(634):1011-2. [QxMD MEDLINE Link].

71. Stefanski JC, Shetty AK. Abdominal pain in a girl with juvenile dermatomyositis. Clin Pediatr (Phila). 1998. 37(9):561-563.

72. Santmyire-Rosenberger B, Dugan EM. Skin involvement in dermatomyositis. Curr Opin Rheumatol. 2003 Nov. 15(6):714-22. [QxMD MEDLINE Link].

73. Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol. 2004 Aug. 31(8):1644-9. [QxMD MEDLINE Link].

74. García-Patos V, Bartralot R, Fonollosa V, Arnal C, Boronat M, Gelpí C. Childhood sclerodermatomyositis: report of a case with the anti-PM/Scl antibody and mechanic's hands. Br J Dermatol. 1996 Oct. 135(4):613-6. [QxMD MEDLINE Link].

75. Pachman LM, Veis A, Stock S, Abbott K, Vicari F, Patel P, et al. Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation. Arthritis Rheum. 2006 Oct. 54(10):3345-50. [QxMD MEDLINE Link]. [Full Text].

76. Wananukul S, Pongprasit P, Wattanakrai P. Calcinosis cutis presenting years before other clinical manifestations of juvenile dermatomyositis: report of two cases. Australas J Dermatol. 1997 Nov. 38(4):202-5. [QxMD MEDLINE Link].

77. Blane CE, White SJ, Braunstein EM, Bowyer SL, Sullivan DB. Patterns of calcification in childhood dermatomyositis. AJR Am J Roentgenol. 1984 Feb. 142(2):397-400. [QxMD MEDLINE Link].

78. Dolezalova P, Young SP, Bacon PA, Southwood TR. Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study. Ann Rheum Dis. 2003 May. 62(5):444-9. [QxMD MEDLINE Link]. [Full Text].

79. Lamminen A, Jääskeläinen J, Rapola J, Suramo I. High-frequency ultrasonography of skeletal muscle in children with neuromuscular disease. J Ultrasound Med. 1988 Sep. 7(9):505-9. [QxMD MEDLINE Link].

80. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogenous patient groups. Medicine (Baltimore). 1991. 70(6):360-74.

81. Chmiel JF, Wessel HU, Targoff IN, Pachman LM. Pulmonary fibrosis and myositis in a child with anti-Jo-1 antibody. J Rheumatol. 1995 Apr. 22(4):762-5. [QxMD MEDLINE Link].

82. Rider LG, Miller FW, Targoff IN, Sherry DD, Samayoa E, Lindahl M. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum. 1994 Oct. 37(10):1534-8. [QxMD MEDLINE Link].

83. Leff RL, Burgess SH, Miller FW, Love LA, Targoff IN, Dalakas MC. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies. Arthritis Rheum. 1991 Nov. 34(11):1391-6. [QxMD MEDLINE Link].

84. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006. 54(11):3682-3689.

85. Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford). 2008. 47(3):324-328.

86. Chan WP, Liu GC. MR imaging of primary skeletal muscle diseases in children. AJR Am J Roentgenol. 2002 Oct. 179(4):989-97. [QxMD MEDLINE Link]. [Full Text].

87. Fraser DD, Frank JA, Dalakas M, Miller FW, Hicks JE, Plotz P. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol. 1991 Nov. 18(11):1693-700. [QxMD MEDLINE Link].

88. Summers RM, Brune AM, Choyke PL, Chow CK, Patronas NJ, Miller FW. Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery MR imaging. Radiology. 1998 Oct. 209(1):191-6. [QxMD MEDLINE Link].

89. Miles L, Bove KE, Lovell D, Wargula JC, Bukulmez H, Shao M. Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Arthritis Rheum. 2007 Oct 15. 57(7):1183-91. [QxMD MEDLINE Link].

90. Wedderburn LR, Varsani H, Li CK, et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis:a tool for potential use in clinical trials. Arthritis Rheum. 2007. 57(7):1192-201.

91. Feldman BM, Ayling-Campos A, Luy L, Stevens D, Silverman ED, Laxer RM. Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire. J Rheumatol. 1995 Feb. 22(2):326-31. [QxMD MEDLINE Link].

92. Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr. 2006 Feb. 148(2):247-53. [QxMD MEDLINE Link].

93. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum. 2008 Feb 15. 59(2):214-21. [QxMD MEDLINE Link].

94. Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford). 2004. 43(4):491-496.

95. Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat. 2004 Jan. 15(1):35-9. [QxMD MEDLINE Link].

96. Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol. 1995 May. 32(5 Pt 1):754-7. [QxMD MEDLINE Link].

97. Ichiki Y, Akiyama T, Shimozawa N, Suzuki Y, Kondo N, Kitajima Y. An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem. Br J Dermatol. 2001 Apr. 144(4):894-7. [QxMD MEDLINE Link].

98. Stringer E, Feldman BM. Advances in the treatment of juvenile dermatomyositis. Curr Opin Rheumatol. 2006 Sep. 18(5):503-6. [QxMD MEDLINE Link].

99. Huang JL. Long-term prognosis of patients with juvenile dermatomyositis initially treated with intravenous methylprednisolone pulse therapy. Clin Exp Rheumatol. 1999 Sep-Oct. 17(5):621-4. [QxMD MEDLINE Link].

100. Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005 Nov. 52(11):3570-8. [QxMD MEDLINE Link].

101. Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol. 1997 Dec. 24(12):2436-43. [QxMD MEDLINE Link].

102. Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford). April 2008. [Full Text].

103. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007 Sep. 56(9):3107-11. [QxMD MEDLINE Link].

104. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial. Arthritis Rheum. 2012 Nov 2. [QxMD MEDLINE Link].

105. Alexanderson H, Dastmalchi M, Esbjörnsson-Liljedahl M, Opava CH, Lundberg IE. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum. 2007 Jun 15. 57(5):768-77. [QxMD MEDLINE Link].

106. Enders FB, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2016 Aug 11. [QxMD MEDLINE Link].

107. Stewart WA, Acott PD, Salisbury SR, Lang BA. Bone mineral density in juvenile dermatomyositis: assessment using dual x-ray absorptiometry. Arthritis Rheum. 2003 Aug. 48(8):2294-8. [QxMD MEDLINE Link].

108. Perez MD, Abrams SA, Koenning G, Stuff JE, O'Brien KO, Ellis KJ. Mineral metabolism in children with dermatomyositis. J Rheumatol. 1994 Dec. 21(12):2364-9. [QxMD MEDLINE Link].

109. Huemer C, Kitson H, Malleson PN, Sanderson S, Huemer M, Cabral DA. Lipodystrophy in patients with juvenile dermatomyositis--evaluation of clinical and metabolic abnormalities. J Rheumatol. 2001 Mar. 28(3):610-5. [QxMD MEDLINE Link].

Ann M Reed, MD Professor of Pediatrics and Medicine, Department of Pediatrics and Medicine, Chair of Pediatric Rheumatology, Research Chair of Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester

Ann M Reed, MD is a member of the following medical societies: American Academy of Pediatrics, Arthritis Foundation

Disclosure: Nothing to disclose.

Floranne Clayton Ernste, MD Associate Professor of Medicine, Division of Rheumatology, Mayo Clinic College of Medicine

Floranne Clayton Ernste, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Rheumatology, Phi Beta Kappa

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Member of Medical Advisory Board for The Myositis Association, Chair of Meeting Committee for IMACS<br/>Served as PI for treatment trial, Octapharma, 2018-2020.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Lawrence K Jung, MD Chief, Division of Pediatric Rheumatology, Children's National Medical Center

Lawrence K Jung, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Immunologists, American College of Rheumatology, Clinical Immunology Society, New York Academy of Sciences

Disclosure: Nothing to disclose.

Jayant Deodhar, MD Associate Professor in Pediatrics, BJ Medical College, India; Honorary Consultant, Departments of Pediatrics and Neonatology, King Edward Memorial Hospital, India

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article